Immune Checkpoint Inhibitor-Induced Type 1 Diabetes Mellitus: Patient Characteristics, Clinical Outcomes, and Survival Implications of Autoantibodies
07:30am - 03:35pm EDT - April 5, 2024


Immune Checkpoint Inhibitor-Induced Type 1 Diabetes Mellitus: Patient Characteristics, Clinical Outcomes, and Survival Implications of Autoantibodies icon

Abstract:  JNCCN23-0675 https://jnccn.org/view/journal...


Author(s):
  • John Sharp, MD, Hematology and Medical Oncology Fellow, The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Tags: Member Institution Outcomes and Health Services Research

Display Label Action
NCCN - ICI T1D Poster 2.29.24.pdf Download Handout